Delving into the Latest Updates on Sennosides with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Senna glycosides, Sennoside, Sennoside A,B

+ [8]

Target-

Action-

Mechanism-

Therapeutic Areas

Other DiseasesNeoplasmsSkin and Musculoskeletal Diseases

Active Indication

ConstipationTriple Negative Breast Cancer

Inactive Indication-

Originator Organization

Sun Pharma Japan Ltd.

Active Organization

Sun Pharma Japan Ltd.

Hubei University of Chinese MedicineHonzo Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

Japan (01 Jul 1967),

Constipation

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC42H38O20

InChIKeyIPQVTOJGNYVQEO-UHFFFAOYSA-N

CAS Registry517-43-1

Colonoscopy Preparation: Comparing Sennoside A+B and PM/Ca
Colonoscopy is a test used to examine the inside of the bowel. Proper bowel preparation is crucial because it helps doctors get a clear view during the procedure.
What is Sennoside A+B? Sennoside A+B is a type of laxative made from the senna plant. It works by stimulating the bowel to move and reducing the absorption of water, making it easier to pass stools. Research has shown that high doses of sennoside A+B can be effective for bowel preparation.
Sennoside A+B vs. PEG:
Some studies have found that sennoside A+B is more effective than PEG, another laxative, but can cause more abdominal pain. Other studies have found no significant difference in effectiveness between the two.
What is Picosulfate/Magnesium Oxide/Citric Acid (PM/Ca)? PM/Ca is a combination of sodium picosulfate, magnesium oxide, and citric acid. Sodium picosulfate stimulates bowel movements, while magnesium oxide and citric acid help increase water in the bowel, making it easier to pass stools.
PM/Ca vs. PEG:
Research has shown that PM/Ca is as effective as PEG for bowel preparation. Patients using PM/Ca generally tolerate the preparation process better than those using PEG.
Conclusion:
While PEG is the preferred option according to guidelines, its high cost can make it less accessible in some places. In this study, we aim to compare the effectiveness and patient tolerance of Sennoside A+B and PM/Ca since no direct comparison between these two preparations has been made before.

Start Date22 Aug 2024

Sponsor / Collaborator

Hittite University

JPRN-jRCT1051220043

/ CompletedNot ApplicableIIT

A prospective, randomized and endoscopist-blinded trial to evaluate comparable efficacy of a 1-L PEG and ascorbic acid with sennoside versus a 2-L PEG and ascorbic acid for bowel preparation - Senno trial

Start Date15 Jun 2022

Sponsor / Collaborator-

NCT03593252

/ Unknown statusNot ApplicableIIT

Pre-Operative Mechanical Bowel Preparation And Prophylactic Oral Antibiotics For Pediatric Patients Undergoing Elective Colorectal Surgery: A Feasibility Randomized Controlled Trial

Infections after elective intestinal surgery remain a significant burden for patients and for the health care system. The cost of treating a single surgical site infection is estimated at approximately $27,000. In adult patients, there is good evidence that the combination of oral antibiotics and mechanical bowel preparation is effective at reducing infections after intestinal surgery. In children, the body of evidence is much weaker. In this population, little evidence exists for oral antibiotics reducing infections and no data exists as to the effect of combining antibiotics with mechanical bowel preparation (such as polyethylene glycol (PEG)). The goal of the proposed study is to examine the effects of oral antibiotics with and without the combined use of mechanical bowel preparation on the rate of post-operative infectious complications in children aged 6 months to 18 years. This will be compared to the institution's current standard of care, which is to abstain from any type of mechanical bowel preparations or oral antibiotic administration before intestinal surgery.

Start Date01 Jan 2022

Sponsor / Collaborator

McMaster University

100 Clinical Results associated with Sennosides

Login to view more data

100 Translational Medicine associated with Sennosides

Login to view more data

100 Patents (Medical) associated with Sennosides

Login to view more data

918

Literatures (Medical) associated with Sennosides

31 Dec 2025·JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

Natural product sennoside B disrupts liquid-liquid phase separation of SARS-CoV-2 nucleocapsid protein by inhibiting its RNA-binding activity

Article

Author: Xu, Xiao-Shuang ; Li, Yimin ; Zhang, Da-Wei ; Xu, Lei ; Xu, Xiaojun ; Xie, Liangxu ; Fu, Zhiguo

The nucleocapsid protein (NP) of SARS-CoV-2, an RNA-binding protein, is capable of undergoing liquid-liquid phase separation (LLPS) during viral infection, which plays a crucial role in virus assembly, replication, and immune regulation. In this study, we developed a homogeneous time-resolved fluorescence (HTRF) method for identifying inhibitors of the SARS-CoV-2 NP-RNA interaction. Using this HTRF-based approach, we identified two natural products, sennoside A and sennoside B, as effective blockers of this interaction. Bio-layer interferometry assays confirmed that both sennosides directly bind to the NP, with binding sites located within the C-terminal domain. Additionally, fluorescence recovery after photobleaching (FRAP) experiments revealed that sennoside B significantly inhibited RNA-induced LLPS of the NP, while sennoside A displayed comparatively weaker activity. Thus, the developed HTRF-based assay is a valuable tool for identifying novel compounds that disrupt the RNA-binding activity and LLPS of the SARS-CoV-2 NP. Our findings may facilitate the development of antiviral drugs targeting SARS-CoV-2 NP.

01 Jul 2025·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Fourier transformed near-infrared combined with chemometric analysis: Sustainable quantification of natural laxatives in Cassia plants

Article

Author: Abaker, Hamza A M ; Tahir, Haroon Elrasheid ; Zheng, Kaiyi ; Hashim, Sulafa B H ; Marappan, Gobinath ; Arslan, Muhammad ; Xiaobo, Zou ; Mahunu, Gustav Komla ; Mariod, Abdalbasit Adam ; El-Seedi, Hesham R ; Karim, Naymul ; Xiaodong, Zhai ; Islam Shishir, Mohammad Rezaul

FT-NIR and chemometrics are vital analytical tools for medicinal plant quality control. This study aimed to establish a rapid technique for quantifying sennoside A and B in Cassia plants (i.e., leaves, pods, and flowers) using Fourier Transformed Near-infrared Spectroscopy (FT-NIR). The calibration models were established by partial least squares (PLS), GA-PLS (Genetic Algorithm PLS), Bi-PLS (Backward Interval PLS), and Si-PLS (Synergy Interval PLS). Sennosides contents in Cassia were quantified using high-performance liquid chromatography. The outcomes indicated that GA-PLS and Si-PLS had the highest correlation coefficient of prediction (R²_p) and lowest root-mean-square error of prediction (RMSEP). Then, the best prediction ability was achieved by Si-PLS (SA: R²_p = 0.9732, RMSEP = 0.9720, 4400.761-4597.464 cm^-1, 5203.003-5399.707 cm^-1, and 5804.685-6001.388 cm^-1; SB: R²_p = 0.9924, RMSEP = 0.1220, 4547.3224-5091.152 cm^-1, 5642.693-6186.521 cm^-1 and 7285.747-7825.718 cm^-1. The external validation of Si-PLS showed excellent results (R²_p > 0.95), offering valuable theoretical guidance for developing an intelligent system to evaluate the quality of Cassia species in real-time.

01 Jul 2025·Endocrine Metabolic & Immune Disorders-Drug Targets

Effects of Ethanol Extract from Senna Leaf (EESL) on Inflammation and Oxidative Stress in Mice: A Non-targeted Metabolomic Study

Article

Author: Yang, Fumeng ; Tan, Jiajun ; Wu, Liang ; Sun, Wen ; Sun, Chang ; Huang, Xiaoli

Background::

Senna leaf is a commonly used medication for treating constipation, and long-term use can cause damage to the intestinal mucosa and lead to drug dependence. But the exact mechanism remains unclear.

Objective::

Using non-targeted metabolomics technology to study the mechanism of senna leaf ethanol extract (EESL) inducing inflammation and oxidative stress in mice and causing side effects.

Methods::

EESL was administered to mice by gavage to detect inflammation and oxidative stressrelated factors in mice, and the EESL components and differential metabolites in mouse plasma were analyzed using non-targeted metabolome techniques.

Results::

23 anthraquinone compounds were identified in the EESL, including sennoside and their derivatives. Administration of EESL to mice resulted in a significant increase in pro-inflammatory factors, IL-1β, and IL-6 in the plasma, while the levels of IgA significantly decreased. The levels of oxidative stress significantly increased, and the intestinal mucosal integrity was impaired. 21 endogenous in plasma metabolites were identified as differential metabolites related with taurine and taurine metabolism, glycerophospholipid metabolism, arachidonic acid metabolism, tryptophan metabolism, and sphingolipid metabolism. These metabolic pathways are related to oxidative stress and inflammation.

Conclusion::

Senna leaf can inhibit the expression of tight junction proteins in the intestinal mucosa and disrupt intestinal mucosal barrier integrity, exacerbating oxidative stress and inflammation induced by bacterial LPS entering the bloodstream. In addition, the impact of Senna leaf on tryptophan metabolism may be linked to the occurrence of drug dependence.

100 Deals associated with Sennosides

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D02171	-	A06AB06	DB11365

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Constipation	Japan	Sun Pharma Japan Ltd.	01 Jul 1967

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Triple Negative Breast Cancer	Discovery	China	Hubei University of Chinese Medicine	13 Feb 2025

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03342157 (CTgov)	Phase 2	Diabetic Gastroparesis	2	docusate+senna (High-dose)	fjnzephzvh(rtukpcwyam) = nyepjzdxus bahxcbotii (xppdlasvhy, fpwwcoaibs - ugwbealitp) View more	-	23 Oct 2020
				docusate+senna (Low-dose)	fjnzephzvh(rtukpcwyam) = nixcgbfjbt bahxcbotii (xppdlasvhy, hwhekvszoe - xwestubiyp) View more
NCT02481219 (CTgov)	Not Applicable	Colorectal Cancer	122	SUPREP oral sulfate solution+Erythromycin+PEG+Metoclopramide+Bisacodyl+Senna tablets (Bowel Preparation Regimen -Control)	lypascxeim = vfmrbxzmiv ybrmirream (lgchhharlg, lqdvzsbcgq - fmhbctvcsp) View more	-	11 Jul 2016
				SUPREP oral sulfate solution with Gastrografin+Erythromycin+PEG+Metoclopramide+Bisacodyl+Senna tablets (Bowel Preparation Regimen-Test)	lypascxeim = tgmptktqkq ybrmirream (lgchhharlg, rhpqpxjjln - ltcobxkdaz) View more
NCT01140295 (CTgov)	Phase 4	-	33	polyethylene glycol+senna (1, Miralax)	twnkzfwqwy = dhqgabwxny xxrhrrbhyv (kxdrssrrfu, llablriwoo - iwjetkrnfi) View more	-	12 Apr 2013
				polyethylene glycol+senna (2, Senna)	twnkzfwqwy = jyimrwxgxj xxrhrrbhyv (kxdrssrrfu, ygkblnkqea - survzjhcjz) View more